Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 06/16/2022 (Stipulation and order of dismissal (voluntary dismissal))

Filing Date: January 18, 2022

According to the Complaint, NRx Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company’s products include, among others, ZYESAMI, an investigational pre-commercial drug.

In June 2021, NRx announced that it filed an application with U.S. Food and Drug Administration requesting Emergency Use Authorization (“EUA”) for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (ii) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On April 6, 2022, the Court issued an Order appointing Lead Plaintiffs and Counsel. Lead Plaintiffs voluntarily dismissed the case on June 13.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.